Related Experiment Video
Updated: Aug 24, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Heart failure management in African Americans: meeting the challenge
1M.D. Anderson Cancer Center, University of Texas, 1515 Holcombe Boulevard No. 449, Houston, TX 77030-4009, USA. jdurand@mdanderson.org
Insights
Heart failure prognosis and treatment may differ in African Americans. Optimal therapy may involve combined beta blockers and angiotensin-converting enzyme inhibitors, with carvedilol showing particular promise.
Area of Science:
- Cardiology
- Clinical Research
- Health Disparities
Background:
- Heart failure (HF) affects 3% of African Americans, with distinct etiology and prognosis compared to other populations.
- Hypertension is a more frequent precursor to HF in African Americans, often leading to more severe target organ damage.
Purpose of the Study:
- To investigate potential differences in optimal heart failure treatment for African Americans.
- To evaluate the efficacy of specific drug combinations in this patient group.
Main Methods:
- Review of large-scale clinical endpoint studies.
- Comparative analysis of treatment outcomes based on race and comorbidities.
Main Results:
- Optimal heart failure treatment in African Americans may differ from non-African Americans.
- Combined use of beta blockers and angiotensin-converting enzyme inhibitors appears effective in African Americans.
- Angiotensin-converting enzyme inhibitors alone may be insufficient therapy for this population.
Conclusions:
- Carvedilol, a beta blocker, may be particularly effective for heart failure treatment in African Americans.
- Tailoring heart failure therapy based on race and comorbidities is crucial for improved outcomes.
Abstract:
Heart failure affects 3% of African Americans. The etiology of disease and prognosis for these patients differs substantially from those for non-African Americans. A history of hypertension is associated with development of heart failure more often in African Americans than in non-African Americans and it also appears that target organ involvement is more severe in African Americans with hypertension than in other patient subgroups. Reviewing the results from large-scale clinical end point studies suggests that optimal treatment for heart failure in African Americans may differ from that of their non-African American counterparts. More importantly, concomitant use of beta blockers and angiotensin-converting enzyme inhibitors may be as effective in African Americans as in non-African Americans. Utilizing angiotensin-converting enzyme inhibitors alone may not represent ideal therapy. Of the drugs studied, especially among the beta blockers, carvedilol may be the most effective to use for this population.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure VII: Nursing Interventions
Heart Failure VI: Adjunct Therapies
Heart Failure IV: Classification and Diagnostic Evaluation
Rheumatic Heart Disease III: Medical Management
Cardiomyopathy VI: Nursing Management